40115 Search Results


mtolylboronic acid  (Chem Impex International)
96
Chem Impex International mtolylboronic acid
Mtolylboronic Acid, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mtolylboronic acid/product/Chem Impex International
Average 96 stars, based on 1 article reviews
mtolylboronic acid - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
mct1 sirna  (Santa Cruz Biotechnology)
91
Santa Cruz Biotechnology mct1 sirna
Mct1 Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mct1 sirna/product/Santa Cruz Biotechnology
Average 91 stars, based on 1 article reviews
mct1 sirna - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier
mct1 knockdown  (Santa Cruz Biotechnology)
92
Santa Cruz Biotechnology mct1 knockdown
<t>MCT1</t> is over-expressed in GBM patients and associates with poor prognosis. ( A ) MCT1 expression level in 10 unmatched normal brains, 27 lower-grade gliomas (LGG), and 572 glioblastomas (GBM) patients from TCGA; *** p < 0.001 and **** p < 0.0001. ( B – I ) Kaplan-Meier survival curves of MCT1 -low and MCT1 -high GBM patients derived from microarray data from ( B ) TCGA dataset, n = 488, median OS 17.6 vs. 13.9 months, low vs. high MCT1 expression, respectively; p = 0.034; (C) REMBRANDT dataset, n = 178, median OS 541 vs. 390 days ( p = 0.018); ( D ) Ducray dataset, n = 52, median OS 16.5 vs. 13.7 months ( p = 0.043); ( E ) Lee Y dataset, n = 191, median OS 16.6 vs. 12.2 months ( p = 0.018); ( F ) Murat dataset, n = 80, median OS 20.9 vs. 14.4 months ( p = 0.003); ( G ) Gravendeel dataset, n = 155, median OS 13.3 vs. 7.8 months ( p = 0.000031); ( H ) Joo dataset, n = 54, median OS 28.4 vs. 16.9 months ( p = 0.022); ( I ) Nutt dataset, n = 28, median OS 38.2 vs. 9.1 months ( p = 0.004); and ( J ) Forest plot of hazard ratios (HR), demonstrating the relationship between MCT1 expression and GBM patients’ overall survival. The HR for each cohort is represented by a black square (its size represents the weight of the study for the meta-analysis) and 95% confidence intervals (CI) by the extending lines. The estimated pooled effect is represented by a red diamond (HR = 1.670; 95% CI, 1.434–1.945; p < 0.0001).
Mct1 Knockdown, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mct1 knockdown/product/Santa Cruz Biotechnology
Average 92 stars, based on 1 article reviews
mct1 knockdown - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
mct1 santa cruz biotech  (Santa Cruz Biotechnology)
90
Santa Cruz Biotechnology mct1 santa cruz biotech
<t>MCT1</t> is over-expressed in GBM patients and associates with poor prognosis. ( A ) MCT1 expression level in 10 unmatched normal brains, 27 lower-grade gliomas (LGG), and 572 glioblastomas (GBM) patients from TCGA; *** p < 0.001 and **** p < 0.0001. ( B – I ) Kaplan-Meier survival curves of MCT1 -low and MCT1 -high GBM patients derived from microarray data from ( B ) TCGA dataset, n = 488, median OS 17.6 vs. 13.9 months, low vs. high MCT1 expression, respectively; p = 0.034; (C) REMBRANDT dataset, n = 178, median OS 541 vs. 390 days ( p = 0.018); ( D ) Ducray dataset, n = 52, median OS 16.5 vs. 13.7 months ( p = 0.043); ( E ) Lee Y dataset, n = 191, median OS 16.6 vs. 12.2 months ( p = 0.018); ( F ) Murat dataset, n = 80, median OS 20.9 vs. 14.4 months ( p = 0.003); ( G ) Gravendeel dataset, n = 155, median OS 13.3 vs. 7.8 months ( p = 0.000031); ( H ) Joo dataset, n = 54, median OS 28.4 vs. 16.9 months ( p = 0.022); ( I ) Nutt dataset, n = 28, median OS 38.2 vs. 9.1 months ( p = 0.004); and ( J ) Forest plot of hazard ratios (HR), demonstrating the relationship between MCT1 expression and GBM patients’ overall survival. The HR for each cohort is represented by a black square (its size represents the weight of the study for the meta-analysis) and 95% confidence intervals (CI) by the extending lines. The estimated pooled effect is represented by a red diamond (HR = 1.670; 95% CI, 1.434–1.945; p < 0.0001).
Mct1 Santa Cruz Biotech, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mct1 santa cruz biotech/product/Santa Cruz Biotechnology
Average 90 stars, based on 1 article reviews
mct1 santa cruz biotech - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
yeast protein ca.40115  (Envigo)
90
Envigo yeast protein ca.40115
<t>MCT1</t> is over-expressed in GBM patients and associates with poor prognosis. ( A ) MCT1 expression level in 10 unmatched normal brains, 27 lower-grade gliomas (LGG), and 572 glioblastomas (GBM) patients from TCGA; *** p < 0.001 and **** p < 0.0001. ( B – I ) Kaplan-Meier survival curves of MCT1 -low and MCT1 -high GBM patients derived from microarray data from ( B ) TCGA dataset, n = 488, median OS 17.6 vs. 13.9 months, low vs. high MCT1 expression, respectively; p = 0.034; (C) REMBRANDT dataset, n = 178, median OS 541 vs. 390 days ( p = 0.018); ( D ) Ducray dataset, n = 52, median OS 16.5 vs. 13.7 months ( p = 0.043); ( E ) Lee Y dataset, n = 191, median OS 16.6 vs. 12.2 months ( p = 0.018); ( F ) Murat dataset, n = 80, median OS 20.9 vs. 14.4 months ( p = 0.003); ( G ) Gravendeel dataset, n = 155, median OS 13.3 vs. 7.8 months ( p = 0.000031); ( H ) Joo dataset, n = 54, median OS 28.4 vs. 16.9 months ( p = 0.022); ( I ) Nutt dataset, n = 28, median OS 38.2 vs. 9.1 months ( p = 0.004); and ( J ) Forest plot of hazard ratios (HR), demonstrating the relationship between MCT1 expression and GBM patients’ overall survival. The HR for each cohort is represented by a black square (its size represents the weight of the study for the meta-analysis) and 95% confidence intervals (CI) by the extending lines. The estimated pooled effect is represented by a red diamond (HR = 1.670; 95% CI, 1.434–1.945; p < 0.0001).
Yeast Protein Ca.40115, supplied by Envigo, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/yeast protein ca.40115/product/Envigo
Average 90 stars, based on 1 article reviews
yeast protein ca.40115 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


MCT1 is over-expressed in GBM patients and associates with poor prognosis. ( A ) MCT1 expression level in 10 unmatched normal brains, 27 lower-grade gliomas (LGG), and 572 glioblastomas (GBM) patients from TCGA; *** p < 0.001 and **** p < 0.0001. ( B – I ) Kaplan-Meier survival curves of MCT1 -low and MCT1 -high GBM patients derived from microarray data from ( B ) TCGA dataset, n = 488, median OS 17.6 vs. 13.9 months, low vs. high MCT1 expression, respectively; p = 0.034; (C) REMBRANDT dataset, n = 178, median OS 541 vs. 390 days ( p = 0.018); ( D ) Ducray dataset, n = 52, median OS 16.5 vs. 13.7 months ( p = 0.043); ( E ) Lee Y dataset, n = 191, median OS 16.6 vs. 12.2 months ( p = 0.018); ( F ) Murat dataset, n = 80, median OS 20.9 vs. 14.4 months ( p = 0.003); ( G ) Gravendeel dataset, n = 155, median OS 13.3 vs. 7.8 months ( p = 0.000031); ( H ) Joo dataset, n = 54, median OS 28.4 vs. 16.9 months ( p = 0.022); ( I ) Nutt dataset, n = 28, median OS 38.2 vs. 9.1 months ( p = 0.004); and ( J ) Forest plot of hazard ratios (HR), demonstrating the relationship between MCT1 expression and GBM patients’ overall survival. The HR for each cohort is represented by a black square (its size represents the weight of the study for the meta-analysis) and 95% confidence intervals (CI) by the extending lines. The estimated pooled effect is represented by a red diamond (HR = 1.670; 95% CI, 1.434–1.945; p < 0.0001).

Journal: Cancers

Article Title: MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma

doi: 10.3390/cancers13143468

Figure Lengend Snippet: MCT1 is over-expressed in GBM patients and associates with poor prognosis. ( A ) MCT1 expression level in 10 unmatched normal brains, 27 lower-grade gliomas (LGG), and 572 glioblastomas (GBM) patients from TCGA; *** p < 0.001 and **** p < 0.0001. ( B – I ) Kaplan-Meier survival curves of MCT1 -low and MCT1 -high GBM patients derived from microarray data from ( B ) TCGA dataset, n = 488, median OS 17.6 vs. 13.9 months, low vs. high MCT1 expression, respectively; p = 0.034; (C) REMBRANDT dataset, n = 178, median OS 541 vs. 390 days ( p = 0.018); ( D ) Ducray dataset, n = 52, median OS 16.5 vs. 13.7 months ( p = 0.043); ( E ) Lee Y dataset, n = 191, median OS 16.6 vs. 12.2 months ( p = 0.018); ( F ) Murat dataset, n = 80, median OS 20.9 vs. 14.4 months ( p = 0.003); ( G ) Gravendeel dataset, n = 155, median OS 13.3 vs. 7.8 months ( p = 0.000031); ( H ) Joo dataset, n = 54, median OS 28.4 vs. 16.9 months ( p = 0.022); ( I ) Nutt dataset, n = 28, median OS 38.2 vs. 9.1 months ( p = 0.004); and ( J ) Forest plot of hazard ratios (HR), demonstrating the relationship between MCT1 expression and GBM patients’ overall survival. The HR for each cohort is represented by a black square (its size represents the weight of the study for the meta-analysis) and 95% confidence intervals (CI) by the extending lines. The estimated pooled effect is represented by a red diamond (HR = 1.670; 95% CI, 1.434–1.945; p < 0.0001).

Article Snippet: For the generation of U251 cells stably expressing shMCT1, a pool of target-specific lentiviral vector plasmids each encoding 19–25 nt (plus hairpin) shRNAs to MCT1 knockdown (sc-37235-SH, Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used.

Techniques: Expressing, Derivative Assay, Microarray

Cox multivariable survival analysis in GBM patients from TCGA.

Journal: Cancers

Article Title: MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma

doi: 10.3390/cancers13143468

Figure Lengend Snippet: Cox multivariable survival analysis in GBM patients from TCGA.

Article Snippet: For the generation of U251 cells stably expressing shMCT1, a pool of target-specific lentiviral vector plasmids each encoding 19–25 nt (plus hairpin) shRNAs to MCT1 knockdown (sc-37235-SH, Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used.

Techniques: Expressing, Biomarker Discovery

Effect of MCT1 downregulation on cell metabolism. Expression of MCT1, MCT4, HKII and HIF-1α in U251 shMCT1 cells by ( A ) Western Blot and ( B ) Immunofluorescence; Western blot MW: HIF-1α 100 kDa, HKII 100 kDa, MCT1 50 kDa, MCT4 44 kDa and β-Actin 42 kDa; Representative pictures was taken at 400× magnification. ( C ) Glucose consumption and lactate production in MCT1 knockdown cells, up to 48 h; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001 U251 shCTRL vs. U251 shMCT1. ( D ) Glucose consumption and lactate production in MCT1 knockdown cells treated with CHC, up to 48 h; * p < 0.05 U251 shCTRL vs. U251 shCTRL + CHC ( E ) Glucose consumption and lactate production in MCT1 knockdown cells treated with ARC155858, up to 48 h; ** p < 0.01; *** p < 0.001 U251 shCTRL vs. U251 shCTRL + ARC155858. Results are representative of three independent experiments, each in triplicate.

Journal: Cancers

Article Title: MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma

doi: 10.3390/cancers13143468

Figure Lengend Snippet: Effect of MCT1 downregulation on cell metabolism. Expression of MCT1, MCT4, HKII and HIF-1α in U251 shMCT1 cells by ( A ) Western Blot and ( B ) Immunofluorescence; Western blot MW: HIF-1α 100 kDa, HKII 100 kDa, MCT1 50 kDa, MCT4 44 kDa and β-Actin 42 kDa; Representative pictures was taken at 400× magnification. ( C ) Glucose consumption and lactate production in MCT1 knockdown cells, up to 48 h; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001 U251 shCTRL vs. U251 shMCT1. ( D ) Glucose consumption and lactate production in MCT1 knockdown cells treated with CHC, up to 48 h; * p < 0.05 U251 shCTRL vs. U251 shCTRL + CHC ( E ) Glucose consumption and lactate production in MCT1 knockdown cells treated with ARC155858, up to 48 h; ** p < 0.01; *** p < 0.001 U251 shCTRL vs. U251 shCTRL + ARC155858. Results are representative of three independent experiments, each in triplicate.

Article Snippet: For the generation of U251 cells stably expressing shMCT1, a pool of target-specific lentiviral vector plasmids each encoding 19–25 nt (plus hairpin) shRNAs to MCT1 knockdown (sc-37235-SH, Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used.

Techniques: Expressing, Western Blot, Immunofluorescence, Knockdown

MCT1 downregulation in glioma cell growth, CHC and AR-C155858 response. ( A ) Cell growth of U251 shCTRL and U251 shMCT1 over time. ( B ) Response of U251 shMCT1 cells to CHC by cell viability assay; IC50 values mean are representative of three independent experiments. ( C ) Response of U251 shMCT1 cells to ARC155858 by cell viability assay. Results are representative of three independent experiments, each in triplicate; ** p < 0.01; **** p < 0.0001 U251 shCTRL vs. U251 shMCT1.

Journal: Cancers

Article Title: MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma

doi: 10.3390/cancers13143468

Figure Lengend Snippet: MCT1 downregulation in glioma cell growth, CHC and AR-C155858 response. ( A ) Cell growth of U251 shCTRL and U251 shMCT1 over time. ( B ) Response of U251 shMCT1 cells to CHC by cell viability assay; IC50 values mean are representative of three independent experiments. ( C ) Response of U251 shMCT1 cells to ARC155858 by cell viability assay. Results are representative of three independent experiments, each in triplicate; ** p < 0.01; **** p < 0.0001 U251 shCTRL vs. U251 shMCT1.

Article Snippet: For the generation of U251 cells stably expressing shMCT1, a pool of target-specific lentiviral vector plasmids each encoding 19–25 nt (plus hairpin) shRNAs to MCT1 knockdown (sc-37235-SH, Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used.

Techniques: Viability Assay

MCT1 inhibition effect on glioma cells TMZ response. ( A ) Response to TMZ in U251 shCTRL and U251 shMCT1; Effect of 300 nM AR-C155858 in TMZ response for U251 shCTRL ( B ) and U251 shMCT1 ( C ). IC50 values mean are representative of three independent experiments.

Journal: Cancers

Article Title: MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma

doi: 10.3390/cancers13143468

Figure Lengend Snippet: MCT1 inhibition effect on glioma cells TMZ response. ( A ) Response to TMZ in U251 shCTRL and U251 shMCT1; Effect of 300 nM AR-C155858 in TMZ response for U251 shCTRL ( B ) and U251 shMCT1 ( C ). IC50 values mean are representative of three independent experiments.

Article Snippet: For the generation of U251 cells stably expressing shMCT1, a pool of target-specific lentiviral vector plasmids each encoding 19–25 nt (plus hairpin) shRNAs to MCT1 knockdown (sc-37235-SH, Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used.

Techniques: Inhibition

In vivo effect of MCT1 knockdown in GBMs overall survival. ( A ) Kaplan-Meier survival curves for in vivo orthotopic intracranial GBM model. Log-rank test shMCT1 vs. shCTRL vs. shMCT1+ TMZ vs. shCTRL+ TMZ, p < 0.0001 n = 11; n = 11; n = 5; n = 5 per group, respectively; ( B ) Hematoxylin-eosin staining of NSG mice brains; Representative pictures of immunohistochemistry for Ki67 in brain tissues of NSG mice at 400× magnification. ( C ) MCT1, MCT4 and CAIX expression in shCTRL and shMCT1 plus TMZ in brain tissues at 400× magnification.

Journal: Cancers

Article Title: MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma

doi: 10.3390/cancers13143468

Figure Lengend Snippet: In vivo effect of MCT1 knockdown in GBMs overall survival. ( A ) Kaplan-Meier survival curves for in vivo orthotopic intracranial GBM model. Log-rank test shMCT1 vs. shCTRL vs. shMCT1+ TMZ vs. shCTRL+ TMZ, p < 0.0001 n = 11; n = 11; n = 5; n = 5 per group, respectively; ( B ) Hematoxylin-eosin staining of NSG mice brains; Representative pictures of immunohistochemistry for Ki67 in brain tissues of NSG mice at 400× magnification. ( C ) MCT1, MCT4 and CAIX expression in shCTRL and shMCT1 plus TMZ in brain tissues at 400× magnification.

Article Snippet: For the generation of U251 cells stably expressing shMCT1, a pool of target-specific lentiviral vector plasmids each encoding 19–25 nt (plus hairpin) shRNAs to MCT1 knockdown (sc-37235-SH, Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used.

Techniques: In Vivo, Knockdown, Staining, Immunohistochemistry, Expressing